Semax is a synthetic peptide made of seven amino acids, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was built from a fragment of the hormone ACTH, specifically the ACTH(4-7) portion, with a proline-glycine-proline tail attached. Russia registered it as a drug and sells it there as nasal drops. It is not approved in the United States for any use. Most published research on Semax comes from rodent studies conducted in Russia.

Is Semax FDA approved?

No. Semax has never been approved by FDA for any indication, and it is not a component of any approved drug. FDA's review also noted that no United States Pharmacopeia monograph exists for it. An advisory committee voted on July 24, 2026 to recommend adding Semax-related substances to the list of bulk substances that compounding pharmacies may use. Law-firm and trade-press accounts report that tally as eight in favour, five against, with one abstention. FDA has not published official minutes. The vote was advisory, and FDA's own review staff had recommended against it.

Is Semax legal in the United States?

Semax is not an approved drug and is not on the 503A bulks list that would permit compounding pharmacies to use it. The July 2026 advisory committee vote recommended adding it but did not change its status. Until FDA completes notice-and-comment rulemaking, no lawful compounding pathway exists. Semax is sold in the United States as a research material for laboratory use, which is a separate category from an approved medicine.

What did the July 2026 FDA vote actually mean?

The Pharmacy Compounding Advisory Committee voted to recommend Semax for the 503A bulks list. Law-firm and trade-press accounts of the July 24, 2026 meeting, including Bass Berry & Sims and the Regulatory Affairs Professionals Society, report eight members in favour, five against and one abstention. FDA has not published official minutes, so that tally rests on those secondary accounts. The committee is a body of outside experts whose role is advisory only. FDA's review team had reached the opposite conclusion, finding the evidence insufficient on characterization, effectiveness and safety. The agency may accept, modify or reject the recommendation.

Can pharmacies compound Semax now?

No. A favourable advisory committee vote is a recommendation rather than an authorization. Semax must appear on the 503A bulks list before a compounding pharmacy may lawfully use it. Adding a substance to that list requires notice-and-comment rulemaking, meaning a proposed rule, a public comment period and a final rule. None of those steps had occurred as of October 2026. FDA's review also found almost no record of Semax being compounded in the first place. No outsourcing facility has reported compounding a Semax product since 2019.

Does Semax increase BDNF?

Rat studies have reported increased expression of brain-derived neurotrophic factor and nerve growth factor after Semax, in some cases within an hour. Separate work in rats with induced ischemia reported growth-factor genes upregulated at three and twenty-four hours. These are animal findings in particular brain regions at particular sampling times. The fold-change figures circulating online vary widely because the underlying studies measured different regions at different hours. FDA's reviewers noted that the mechanism by which Semax changes gene expression remains unknown. No equivalent human measurement was located for this review.

Does Semax raise dopamine?

Not on its own, according to the study usually cited for that claim. In mice, Semax potentiated dopamine release that amphetamine produced, so the effect depended on amphetamine being present. The same research group reported that Semax raised a serotonin metabolite in the striatum in a dose-dependent way. FDA treated the dopamine result as a safety concern rather than a benefit. Reviewers noted that raised striatal dopamine tone is characteristic of drugs of abuse. They also noted that no study has assessed whether Semax has reinforcing or addictive properties.

What is Semax used for in Russia?

Semax is a registered drug in Russia, and FDA confirmed that status by searching the Russian medicines register directly. It is sold there as nasal drops in two strengths. Published Russian work has examined it in chronic ischemic brain disease, peptic ulcer and pain conditions. Much of that literature is written in Russian and has not been assessed by Western regulators. Registration in one country establishes nothing about United States regulatory status. It also does not demonstrate effectiveness by the evidentiary standards FDA applies to a drug substance.

Does Semax work for migraine?

The only study FDA identified was small, uncontrolled and unblinded. Twelve adults received a single intranasal dose. Four reported their headache stopped 90 to 120 minutes later, while eight reported pain that was reduced but still present. FDA concluded there was insufficient evidence of effectiveness. Reviewers pointed to the absence of a control group, the absence of blinding, and the lack of published scores or standard deviations. The rating scale the authors used was never described. Professional society guidelines on migraine treatment do not discuss Semax at all.

What are the side effects of Semax?

Very little has been formally measured, which is different from saying the compound is well tolerated. Most published human reports did not discuss adverse events at all, and only one stated that none were observed. FDA's adverse event database held a single report. A consumer described ocular pain and eye burning after using Semax nasal drops bought online, with hospitalization and symptoms unresolved a year later. Reviewers also flagged a potential bleeding risk, drawn from rat findings that Semax reduces clotting. Immunogenicity from peptide aggregates remains an open concern that no study has addressed.

What is the difference between Semax and N-acetyl Semax?

Base Semax is the seven-amino-acid molecule described throughout this article. N-acetyl Semax carries an acetyl modification at one end, and the amidated version modifies both ends. They are chemically different substances, and research findings for base Semax do not automatically apply to them. FDA's 2026 evaluation examined only Semax free base and Semax acetate, so the modified variants were never assessed. Reviewers separately warned that multiple salts and derivatives circulate commercially under the single name Semax. They described that naming inconsistency as a safety risk for patients.

Is Semax the same as Selank?

No. They are different molecules built from different parent compounds. Semax derives from an ACTH fragment, while Selank derives from a fragment of tuftsin. Both carry a proline-glycine-proline extension, and both came out of Russian peptide research. Selank was not among the seven peptides FDA's advisory committee reviewed in July 2026. When nominators submitted a paper on Selank as part of the Semax package, FDA set it aside because Selank is a different peptide. Some vendors sell fixed combinations of the two, which is not evidence that the pairing was ever studied.

Is Semax banned in sport?

Semax does not appear by name on the WADA Prohibited List. Articles often state that it falls automatically under category S0, which covers substances not approved by any governmental regulatory health authority. That reading is complicated, because Semax is approved in Russia. The Prohibited List is also explicitly not exhaustive, and other catch-all categories could apply to a peptide with claimed performance effects. The practical position for a competing athlete is that the status is uncertain and the risk is high. Verify through official anti-doping resources rather than any article, including this one.

Semax: FDA Said No, the Panel Said Yes

Q: What is the half-life of Semax?

No human pharmacokinetic study of Semax exists. FDA stated directly that it could not find pharmacokinetic studies in humans following exposure by any route. Any half-life figure on a vendor page is therefore unsupported by human data. The available numbers come from rat studies using radioactive labelling, which measured how much reached the brain rather than human clearance. Those studies found that Semax breaks down quickly in rat blood and brain tissue. The proline-glycine-proline tripeptide was the main metabolite recovered from both.

Semax is a synthetic seven-amino-acid peptide built from a fragment of ACTH. Russia registered it decades ago and still sells it as nasal drops. United States regulators reviewed it in 2026 and found the human evidence too thin to support any of the three uses they examined. Most published work remains in rodents.

In July 2026, something unusual happened to Semax. An FDA advisory committee voted to recommend it for the list of substances that compounding pharmacies may use. FDA's own review scientists had recommended the opposite. They had just finished a document concluding that the evidence weighed against Semax on nearly every criterion the agency applies.

Both of those things are true at the same time. A committee of outside experts voted in favour. Law-firm and trade-press accounts of the meeting report the tally as eight to five, with one abstention. The agency's reviewers had written that the available data was insufficient. That split is the most interesting fact about Semax right now, and almost nobody writing about it explains why it happened.

This article works through what the research actually establishes. It covers the molecule and the mechanisms studied in animals. It also covers the small human literature, the regulatory record, and the many places where published numbers disagree. Where the evidence is weak, this article says so.

PrimeTime BioLabs supplies Semax as a research material. That is a separate matter from what the science shows, and this page does not blur the two.

How this article grades evidence

Peptide articles often present a rodent finding and a human trial in the same sentence. Readers deserve a clearer separation than that. Every claim below carries one of five labels.

A study in people with a control group and, ideally, blinding.

A study in people with no control group, no blinding, or both.

A finding in rats or mice.

A finding in cells, tissue, or a test tube.

Searched for and not found.

Semax has no entries in the first category. Not one. That single fact shapes everything that follows.

What Semax actually is

A heptapeptide is a molecule of seven amino acids, and that is what Semax is. Its sequence runs Met-Glu-His-Phe-Pro-Gly-Pro, often written MEHFPGP.

The molecule was built from a piece of adrenocorticotropic hormone, usually shortened to ACTH. Writers describe Semax as an analog of the ACTH(4-10) fragment, and FDA's own review uses that phrasing. The more precise description is different. Semax takes the ACTH(4-7) fragment, which is Met-Glu-His-Phe, and attaches a proline-glycine-proline tail to the end.

Those two descriptions get treated as interchangeable across the web. The two descriptions are not interchangeable. ACTH(4-10) and Semax differ at the last three amino acid positions, as FDA's briefing document sets out directly. Calling Semax "ACTH(4-10) plus PGP" implies a ten-residue backbone that the molecule does not have.

The proline-glycine-proline tail does a specific job. Published work points to it slowing the enzyme breakdown that destroys the native ACTH fragment quickly. That describes a stability property of the molecule. It is not melanocortin receptor activation of the kind native ACTH produces, and the distinction matters when reading mechanism papers.

One more identity problem deserves attention. Semax free base and Semax acetate are different substances. FDA evaluated them separately and said so plainly. They carry different molecular formulas, different molecular weights, and different registry numbers.

Semax identity at a glance

Sequence — Semax (free base): H-Met-Glu-His-Phe-Pro-Gly-Pro-OH — Semax acetate: Same sequence, acetate salt
CAS number — Semax (free base): 80714-61-0 — Semax acetate: 2828433-33-4
Molecular formula — Semax (free base): C₃₇H₅₁N₉O₁₀S — Semax acetate: C₃₉H₅₅N₉O₁₂S
Molecular weight — Semax (free base): 813.93 g/mol — Semax acetate: approximately 874.0 g/mol
FDA UNII code — Semax (free base): I5FAL2585H — Semax acetate: Not available

Figures above come from FDA's July 2026 briefing document, which matches PubChem for the free base. The PrimeTime BioLabs product page reports the same free-base figures.

FDA raised a related warning that sellers rarely repeat. The agency wrote that "Semax" is a common name rather than a formal one. Multiple salts and derivatives circulate commercially under that single label. Reviewers called this a safety risk, because a buyer may receive a different substance than the one they believed they ordered.

Semax, N-acetyl Semax, and the amidated form

Online sellers list several modified versions. Base Semax is the molecule described above. N-acetyl Semax adds an acetyl group at one end. N-acetyl Semax amidate, often abbreviated NASA, modifies both ends.

Vendors commonly carry claims about these variants directly across from the parent molecule. That transfer of claims has no support in the literature. Research conducted on base Semax says nothing reliable about a chemically modified version. FDA's 2026 review examined only the free base and the acetate salt. The variants were not part of that evaluation at all.

Where Semax came from

Semax came out of Soviet and Russian peptide research rather than Western pharmaceutical development. FDA's briefing document names the source of the Semax used in one published study. It was synthesized at the Laboratory of Regulatory Peptides, Institute of Molecular Genetics, Russian Academy of Sciences.

The compound was designed around a specific question about ACTH. Researchers wanted the behavioural and neural properties associated with the hormone fragment, without the hormonal effects that normally come with it. The published account of Semax describes that outcome directly.

Russia registered Semax as a drug, and that registration still stands. FDA confirmed the status by searching the Russian medicines register. The product is sold there as nasal drops in two strengths, 0.1 percent and 1 percent.

Western pharmacopoeias never followed that Russian registration. FDA checked the European Pharmacopoeia, the Japanese Pharmacopoeia, and the International Pharmacopoeia. No monograph for Semax appears in any of them, and none appears in the United States Pharmacopeia either.

Is Semax a nootropic

The word gets attached to Semax constantly, and FDA's handling of it is instructive. Semax was formally nominated for "nootropic" use alongside its other proposed uses.

Reviewers could not evaluate that nomination as written. They noted that "nootropic" carries no diagnostic code, and that no professional society guidelines exist for it. The agency fell back on a dictionary definition and folded the question into its cerebral ischemia assessment instead.

That exchange is a useful reminder. "Nootropic" is a marketing category rather than a medical one, and regulators cannot assess a claim that names no condition.

What animal research has examined

Most Semax research sits in rodents. The findings below are real experimental results. None of them establish a human outcome.

Neurotrophic signaling

Rat studies have reported increased expression of brain-derived neurotrophic factor and nerve growth factor after intranasal Semax. One frequently cited study observed those increases across several brain regions, including the hippocampus, within an hour of treatment. Gene-expression work in rats with induced ischemia reported upregulation of growth-factor genes at three and twenty-four hours.

*Animal evidence.* The mechanism by which Semax changes gene expression remains unknown, as FDA's reviewers noted.

Ischemia models

In a rat model of focal clot-induced ischemia, treated animals had damaged brain areas roughly 20 percent smaller than untreated animals after eight days. The treated rats also avoided a memory deficit that the vehicle group showed.

A separate study in rats with ischemia from carotid occlusion reported reduced tissue damage and more cells expressing a DNA repair protein.

*Animal evidence.* FDA flagged a real limit on this work. These studies tested a single fixed amount. Without a dose-response curve, and without measuring systemic exposure, the findings cannot be scaled to anything else.

Pain

Rodent analgesia results depend heavily on route, and this is one of the more revealing findings in the whole literature. In one study, Semax given by intraperitoneal injection raised pain thresholds in a dose-dependent way. The same amounts given intranasally produced no analgesia at all.

Follow-up work suggested the effect runs through serotonin signaling rather than opioid signaling. An opioid blocker failed to prevent it. A serotonin receptor antagonist did prevent it.

In-vitro work points to one more possible route. Semax inhibits enkephalinases, the enzymes that break down the body's own opioid peptides. Radiolabelled Semax also binds to membrane targets in rat brain tissue. Blocking those enzymes would raise local opioid levels, which could contribute to analgesia. The naloxone result argues against that being the main mechanism.

*Animal and in-vitro evidence.* Route changed the outcome completely, which should make anyone cautious about generalizing from one administration method to another.

The dopamine finding people misreport

A widely repeated claim holds that Semax raises dopamine. The underlying study found something narrower. Semax potentiated amphetamine-induced dopamine release in mouse striatum. The dopamine effect was conditional on amphetamine being present.

FDA treated this finding as a concern rather than a benefit. Reviewers noted that raised striatal dopamine tone is characteristic of drugs of abuse, and that no studies exist assessing whether Semax has reinforcing properties.

*Animal evidence.* Reporting this as "Semax increases dopamine" drops the condition that makes the result meaningful.

The cortisol question

Semax derives from ACTH, and ACTH drives cortisol release. People reasonably ask whether Semax does the same thing.

Published work says it does not. The literature FDA cited describes Semax as lacking the hormonal corticotropic and melanotropic properties of the full-length hormone, while keeping the neurobehavioural ones. That separation was the original design goal. It is also the clearest reason Semax is not simply a shortened ACTH molecule.

*Animal and in-vitro evidence.* No human hormone measurement following Semax was located for this review.

What happens to the molecule after it is given

Rat studies traced the fate of labelled Semax, and those results explain several other findings.

The molecule breaks down quickly in rat blood and brain tissue. Enzymes strip amino acids from one end in sequence, producing a series of shorter fragments. The proline-glycine-proline tripeptide was the main metabolite found in both blood and brain.

That detail matters more than it first appears. Some effects attributed to Semax may belong to its breakdown products rather than the parent molecule. The anticoagulant findings are a clear case, since the tripeptide fragment carries that activity on its own.

Route also changed how much reached the brain. Intranasal administration delivered a higher fraction to rat brain than intravenous administration did, and it arrived within two minutes.

*Animal evidence.* No equivalent measurement exists in people.

Blood clotting

Several rat studies report anticoagulant and clot-dissolving effects. One found reduced platelet aggregation of roughly 35 percent. Another reported that Semax protected rats from the clotting changes that stress produces.

FDA read that same literature and reached a careful conclusion. The studies used fixed amounts, and no dose-response data exists. Reviewers wrote that it is unclear whether Semax could correct excess clotting without pushing toward a bleeding risk.

*Animal evidence.* Interestingly, the proline-glycine-proline fragment that Semax breaks down into carries anticoagulant activity of its own.

What the human research actually found

Here is where the picture thins dramatically. FDA searched PubMed, Embase, the Cochrane database, ClinicalTrials.gov, and professional guidelines. For effectiveness, reviewers located exactly two usable references.

The table below adjudicates the human literature that FDA identified. No study in it has a control group.

Koroleva 1996, migraine — Population and design: 12 adults, single intranasal dose, open label — What was reported: 4 of 12 reported headache stopped 90 to 120 minutes later; the other 8 reported pain reduced but still present — Evidence grade: Uncontrolled human — Main limitation: No control, no blinding, no actual scores or standard deviations published, rating scale never described
Koroleva 1996, typical trigeminal neuralgia — Population and design: 16 adults, single intranasal dose, open label — What was reported: No change in pain characteristics, sensation thresholds, or evoked potentials — Evidence grade: Uncontrolled human — Main limitation: Authors concluded Semax does not show analgesic activity on its own
Koroleva 1996, dental plexalgia — Population and design: 9 adults, single intranasal dose, open label — What was reported: Pain resolved in 6 and decreased in 3, but attack frequency and duration did not fall — Evidence grade: Uncontrolled human — Main limitation: Same design limits; results reported in arbitrary units
Cherkasova 2002, chronic ischemic brain disease — Population and design: Number of human subjects not stated; meeting abstract only — What was reported: Clotting-related lab values measured; full results never given — Evidence grade: Uncontrolled human — Main limitation: No full publication exists; no clinical function reported before or after
Ivanikov 2002, peptic ulcer — Population and design: 32 adults, Semax added to standard drug therapy — What was reported: Reported alongside standard treatment — Evidence grade: Uncontrolled human — Main limitation: Three other drugs given at the same time, so no effect can be attributed to Semax
Kaplan 1996, healthy volunteers — Population and design: 19 healthy adult men — What was reported: Attention improvement reported — Evidence grade: Uncontrolled human — Main limitation: Small, healthy subjects, no control group
Lebedeva 2018 and Panikratova 2020 — Population and design: 14 healthy adults — What was reported: Imaging and recording studies — Evidence grade: Uncontrolled human — Main limitation: FDA noted the subjects may be the same people counted twice
Proskurina 2018, pediatric depression — Population and design: 120 children aged 12 to 14 — What was reported: Semax given with therapy and physiotherapy — Evidence grade: Uncontrolled human — Main limitation: Meeting abstract; multiple simultaneous treatments
Aminova 2016, tics and Tourette syndrome — Population and design: 331 children — What was reported: Semax given with two other drug classes — Evidence grade: Uncontrolled human — Main limitation: Meeting abstract; multiple simultaneous treatments

Across every published report FDA located, Semax reached between 33 and 47 healthy adults. It also reached 69 adults with medical conditions and 451 children. That is the entire documented human exposure base.

The missing Russian stroke literature

Semax is best known for stroke. Yet the table above contains no stroke trial, and the reason is procedural rather than scientific.

FDA identified Russian-language publications on Semax and cerebral ischemia, including several by Gusev and colleagues. Reviewers did not consider any of those papers. Agency rules require foreign-language submissions to arrive with a verified English translation, and no translations were provided.

That situation leaves an honest gap in the record. Russian stroke research on Semax may contain useful data. It has not been assessed by Western regulators, and an English-language reader cannot evaluate it directly. Anyone claiming Semax is "proven" for stroke is relying on literature that the relevant regulator declined to read.

What the evidence does not show

Most competing pages list benefits and stop there. Very few list the negatives, so this section collects them.

Every human study above lacks a control group.

FDA stated it could not find pharmacokinetic studies in humans after Semax exposure by any route. Not intranasal, not injected, not any route.

The Alzheimer's Drug Discovery Foundation's Cognitive Vitality report found little evidence on whether Semax would improve cognition in healthy patients. It found no evidence at all for Alzheimer's disease.

In the one study examining it, patients with typical trigeminal neuralgia showed no change on any measure.

FDA reported finding no acute toxicity studies, no repeat-dose toxicity studies, no developmental or reproductive toxicity studies, and no adequate carcinogenicity study.

FDA noted that Semax had been nominated for ADHD but that supporting literature could not be found, so the agency did not assess it.

The only route discussed anywhere in the human literature was intranasal.

What about the focus, ADHD and anxiety claims

Most Semax marketing rests on three claims that the regulatory record does not support.

ADHD never received an evidence assessment at all. FDA noted the nomination and reported that supporting literature could not be found, so the agency did not evaluate it.

Anxiety has animal support and no human trial that this review located. Rodent studies report antidepressant-like and anxiolytic-like behaviour. Those are observations in behavioural assays rather than clinical outcomes in people.

Focus and memory claims rest mainly on small studies in healthy volunteers. The Alzheimer's Drug Discovery Foundation reviewed this area and found little evidence on cognition in healthy people.

Evidence grade: Animal evidence for anxiety-like behaviour. No evidence located for ADHD. Uncontrolled human evidence for attention in healthy volunteers.

Why published Semax numbers disagree

Conflicting figures circulate constantly across vendor pages. Three explain most of the confusion.

Vendor pages confidently state a Semax half-life, usually in minutes. No human pharmacokinetic study exists to support any such figure. The underlying numbers come from rat studies using radioactive labeling. In rats given it intravenously, peak brain levels represented about 0.005 percent of the amount given. Given intranasally, peak brain levels reached about 0.072 percent, and arrived within two minutes. Those are rat figures measuring brain uptake, not a human half-life.

Fold-change figures vary widely because the underlying studies sampled different brain regions at different hours after administration. A number without its region and its timing is not a usable number.

As covered earlier, Semax is ACTH(4-7) with a three-residue tail, not ACTH(4-10) with a tail added. The second phrasing appears across vendor content and produces a molecule that does not exist.

Figures we checked and chose not to use

Several claims circulating about Semax could not be substantiated well enough to publish.

Any stated human half-life was excluded, because FDA found no human pharmacokinetic data by any route.

Precise BDNF fold-change figures were excluded wherever the source did not specify brain region and sampling time.

Pharmacokinetic claims about N-acetyl Semax and the amidated form were excluded. Those figures are generally carried over from the parent molecule rather than measured.

Performance statistics attributed to military or operator populations were excluded. No underlying study could be located for them.

Where Semax stands with the FDA right now

This section is current as of October 16, 2026.

Semax is not approved by FDA for any use. It has never been approved for any indication in the United States.

In April 2026, FDA announced that twelve peptides, Semax among them, would come off Category 2 of the 503A bulk drug substances list. Category 2 covers substances the agency has flagged as raising significant safety risks. Removal took effect April 22, 2026.

Why it happened matters, and most coverage gets it wrong. The peptides came off Category 2 because the parties who nominated them withdrew their nominations. FDA did not reassess them as safe. Removal also did not place them on any approved list. Analysts described the result as leaving the substances in limbo.

FDA then scheduled its Pharmacy Compounding Advisory Committee to review seven peptides on July 23 and 24, 2026. Semax was reviewed on the second day, alongside Epitalon and emideltide.

Why the staff and the committee disagreed

FDA's review team produced a briefing document dated May 11, 2026. It evaluated Semax free base and Semax acetate for cerebral ischemia, migraine, and trigeminal neuralgia. The conclusion they reached was unambiguous. Reviewers proposed not adding either substance to the list.

Their reasoning rested on four findings. The substances were not well characterized chemically. Inconsistent naming was part of the problem, and quality data on impurities, aggregates, and endotoxins could not be found. The record of historical compounding use was unclear. Effectiveness evidence was insufficient for all three uses. Safety information was insufficient, with immunogenicity concerns attached to both proposed routes.

The committee voted the other way. Law-firm and trade-press accounts of the meeting report eight members in favour, five against and one abstention. Those accounts include Bass Berry & Sims and the Regulatory Affairs Professionals Society. FDA has not published official minutes of the vote, so that tally rests on those secondary accounts. Five other peptides also received favorable votes against staff recommendations. Emideltide was the only one rejected.

So what explains a divergence that wide? The committee is an advisory body of outside experts. It weighs the agency's analysis but is not bound by it, and committee members raised considerations beyond the briefing document. One member observed that clinicians appear to use Semax more often for migraine, brain fog, and cognitive support than for acute stroke. That raised a question about whether FDA had evaluated the right uses.

A staff recommendation and a committee vote are different instruments. Neither one amounts to an agency decision.

Whether pharmacies ever actually compounded it

One of FDA's criteria asks whether a substance has a real history of use in compounding. The answer for Semax came close to nothing.

Nominators stated that Semax had been used in compounding but supplied no supporting detail. They submitted 38 articles, and FDA reported that none of them discussed a compounded Semax formulation. A search identified no pharmacy marketing a Semax product.

No outsourcing facility has reported compounding anything containing Semax since 2019. The one documented instance FDA found came from a Department of Justice press release about a Kentucky pharmacy, and that case concerned unlawful distribution.

What reviewers did find was a busy retail market. They listed wellness clinics, concierge medical services, regenerative medicine practices, and online retailers selling Semax injection and nasal products. Catalogued marketing claims ran from anxiety and depression through stroke, ADHD, Parkinson's disease, Alzheimer's disease, and optic nerve atrophy. Most of those sites never stated which chemical form they were selling.

What the vote changed, and what it did not

The vote changed nothing about legal status.

Adding a substance to the 503A bulks list requires formal rulemaking. That means a proposed rule, a public comment period, and a final rule. No such rulemaking has begun for Semax. The list itself sits in federal regulation and contains a small number of substances, none of which is Semax.

FDA is free to accept the recommendation, modify it, or reject it. Until the agency completes rulemaking, no compounding pathway for Semax exists in the United States. Our guide to US peptide law covers the broader framework.

Russia is the one country where Semax holds a registration. FDA's briefing document records that it is a registered drug there, sold as nasal drops in two strengths. A foreign registration establishes nothing about US status and does not demonstrate effectiveness by the standards FDA applies.

Anti-doping status

Semax does not appear by name on the WADA Prohibited List. Writers often claim it falls automatically under category S0, which covers substances not approved for human use.

Read closely, that claim is shakier than it sounds. S0 applies to substances not approved by any governmental regulatory health authority. Semax is approved in Russia, which complicates a straightforward S0 reading. The list is also explicitly not exhaustive, and other catch-all categories could apply.

Any competing athlete should treat Semax as high risk and verify through official anti-doping channels rather than any article, including this one.

Semax and Selank compared

These two peptides get discussed as a pair constantly. Both came out of Russian peptide research. Both are sold by the same vendors. The comparison deserves more care than it usually gets.

Structure — Semax: Seven amino acids, built from ACTH(4-7) with a Pro-Gly-Pro tail — Selank: Built from a fragment of tuftsin with a similar Pro-Gly-Pro extension
Main research focus — Semax: Neurotrophic signaling, ischemia models, analgesia — Selank: Anxiety-related and immune-related research
July 2026 FDA committee review — Semax: Reviewed and recommended; trade-press accounts report 8 to 5 with one abstention — Selank: Not among the seven peptides reviewed
US approval — Semax: None — Selank: None
Controlled human trials identified here — Semax: None — Selank: Not assessed in this review

Two honest caveats belong alongside that table.

First, PrimeTime BioLabs does not supply Selank, and this review verified Semax claims against primary records rather than Selank claims. Statements about Selank's mechanisms and trials circulate widely and were not independently adjudicated for this article. Treating that section of the internet as settled would be a mistake.

Second, readers frequently ask whether the two are used together. No controlled research on the combination was located. That is the complete answer available, and anything beyond it would be speculation presented as guidance.

The combination question has a commercial origin worth noting. FDA's survey of the retail market found vendors selling fixed Semax and Selank combination products, in both injectable and nasal formats. A product existing on a shelf is not evidence that the pairing was ever studied.

FDA also drew a boundary that tells you something about the two molecules. Nominators submitted a paper on Selank analgesia as part of the Semax package. Reviewers set it aside as out of scope, because Selank is a different peptide. Regulators treat them as separate substances even when sellers bundle them.

A note on scope: the research-use framing of this site means it covers what studies examined, not how anyone should use a compound.

Safety, and the large gaps in it

Vendor pages tend to call Semax well tolerated. The accurate statement is that very little has been measured.

Most published human reports did not discuss adverse events at all. One reported that no adverse events were observed. The rest were silent, which is different from reporting safety.

Three specific concerns appear in the regulatory record.

FDA linked the rat anticoagulant findings to a real-world question. Reviewers wrote that the antithrombotic properties raise concern about bleeding risk, particularly in people already prone to bleeding or taking other medicines that affect clotting. Compounded products carry no labeling that would warn about this.

Peptides can clump together into aggregates, and aggregates raise the chance of an immune response. FDA could not find any study assessing aggregation or immunogenicity for either Semax substance, and could not rule the risk out.

Standard drug development produces acute toxicity studies, repeat-dose studies, genotoxicity testing, reproductive toxicity work, and a two-year carcinogenicity study. FDA looked for each of these and found none. The closest match was a study in tumour-prone mice treated for under three months, which reviewers judged inadequate for assessing cancer risk.

FDA searched its adverse event reporting system through December 2025 and retrieved one report. A consumer described ocular pain and eye burning in May 2024 after using Semax nasal drops bought online. The report states she was hospitalized, and that the eye pain had not resolved a year later. One report proves little about frequency, but it is the only human adverse event formally on record.

Long-term safety data does not exist in any Western sense. Decades of Russian prescribing is a meaningful observation, and it is not the same thing as controlled follow-up.

What a certificate of analysis can and cannot establish

Research material arrives with analytical documentation, and that documentation is often misread.

A certificate reporting high purity by chromatography, with identity supported by mass spectrometry, establishes two things about one batch. It indicates chemical purity relative to detectable components, and it provides evidence consistent with the expected molecule.

It establishes nothing about sterility, biological activity, or safety in any living system. FDA's review made a related point from the regulator's side. Reviewers noted that the certificates they examined lacked testing for aggregates, microbial load, and bacterial endotoxins. Those gaps feed directly into the immunogenicity concern.

Our guide to reading a certificate of analysis covers the technical detail, and our supplier due-diligence checklist covers what to ask a vendor. The Semax 10 mg research material PrimeTime BioLabs supplies is sold for laboratory and in-vitro work by qualified professionals. Nothing on this page describes a property of that product.

Who funded this research, and who wrote this page

Readers should be able to see who paid for the science and who wrote the summary. Both answers here are less satisfying than they ought to be.

Funding of the cited studies

FDA's briefing document is the source inspected for the study details in this article. It summarizes designs, populations and results. It does not report funding or sponsorship for any study it cites, so the entries below say so plainly rather than guessing.

Koroleva 1996, migraine and trigeminal neuralgia — Funding or sponsorship: Not reported in the source inspected
Cherkasova 2002, ischemic brain disease and rat clotting — Funding or sponsorship: Not reported in the source inspected
Ivanikov 2002, peptic ulcer — Funding or sponsorship: Not reported in the source inspected
Kaplan 1996, healthy volunteers — Funding or sponsorship: Not reported in the source inspected
Lebedeva 2018 and Panikratova 2020, healthy volunteers — Funding or sponsorship: Not reported in the source inspected
Proskurina 2018 and Aminova 2016, paediatric reports — Funding or sponsorship: Not reported in the source inspected
Romanova 2006 and Stavchansky 2011, rat ischemia — Funding or sponsorship: Not reported in the source inspected
Agapova 2007 and Medvedeva 2014, gene expression — Funding or sponsorship: Not reported in the source inspected
Eremin 2004 and 2005, monoamine findings — Funding or sponsorship: Not reported in the source inspected
Manchenko 2012 and Ivanova 2003 to 2007, analgesia — Funding or sponsorship: Not reported in the source inspected
Potaman 1991 and Shevchenko 2006, rat pharmacokinetics — Funding or sponsorship: Not reported in the source inspected
Meshavkin 2013, mouse tumour study — Funding or sponsorship: Not reported in the source inspected
Cognitive Vitality report — Funding or sponsorship: Produced by the Alzheimer's Drug Discovery Foundation, a non-profit organization

One independence consideration is visible even without funding statements. Semax was developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Several of the most-cited mechanism papers carry author names associated with that institute.

That is an observation about authorship rather than a funding finding. It is also a reason to want independent replication outside the institution that created the molecule.

Independence of this article

PrimeTime BioLabs sells Semax as a research material, and this page sits on the company's own website. That is a commercial interest, and readers should weigh it when reading anything here.

Three editorial choices follow from that interest. This article carries no discount code, no pricing and no purchase prompt. Its conclusions come from FDA's published record and a named non-profit assessment, not from sources the company controls. Where the evidence is weak or missing, the article says so, including where saying so is commercially unhelpful.

Where this leaves Semax

Semax occupies an unusually awkward position. A national government registered it as a drug. Clinicians in that country have used it for decades. An FDA advisory committee just voted in its favor. None of that is the same as evidence.

Strip the regulatory noise away and the scientific picture is clear enough. Rodent work is reasonably extensive and points toward neurotrophic and neuroprotective activity through mechanisms nobody has pinned down. Human work consists of a handful of small, uncontrolled studies, one of which returned a negative result for the condition it examined. The stroke literature everyone cites sits behind a language barrier that regulators declined to cross.

That combination deserves genuine scientific curiosity and considerable restraint. Readers need to hold both of those at once.

The regulatory picture will certainly keep moving. A proposed rule could appear, or FDA could decline the recommendation entirely. This page carries a review date for that reason, and will be updated as the record changes.